Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INTERVIEW: Scottish Medicines Consortium – future-proofing for personalized medicines

This article was originally published in Scrip

Executive Summary

News that Scotland is to develop its own value-based assessments for drugs, rather than wait for England to finally come through with its own value-based pricing system, came as something as a relief for Angela Timoney, chair of Scotland's influential health technology appraisal institute, the Scottish Medicines Consortium. The decision means that SMC can finally move forward with changing the way it assesses and-of-life and ultra-orphan drugs, which in turn will help prepare for a future that will inevitably mean dealing with more personalized medicines, she told Scrip.

You may also be interested in...



Decision On Covid-19 TRIPS Waiver Postponed

WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.

German Insurers Want End To Free Pricing In Amnog Review

Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.

Investors Spooked By High Prices For Advanced Therapies

To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.

Topics

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel